TRCT
LABT

Tower Research Capital (TRC)’s Lakewood-Amedex Biotherapeutics LABT Stock Holding History

Tower Research Capital (TRC)’s Portfolio LABT Stock Details LABT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96K Buy
+624
New +$10.7K ﹤0.01% 4739

Other funds holding LABT

MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Tower Research Capital (TRC)'s LABT Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Lakewood-Amedex Biotherapeutics (LABT) in Q2 2026: 624 shares worth $1.96K. The stake represents ﹤0.01% of the portfolio and ranks #4739 among its holdings.

6 funds tracked by Wall St. Rank hold LABT as of Q2 2026.

  • Tower Research Capital (TRC) held 624 shares of Lakewood-Amedex Biotherapeutics worth $1.96K as of Q2 2026.
  • Lakewood-Amedex Biotherapeutics was a new Tower Research Capital (TRC) position in Q2 2026.
  • Lakewood-Amedex Biotherapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4739 holding.
  • 6 funds tracked by Wall St. Rank held Lakewood-Amedex Biotherapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.